EDEM2抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P02431(EDEM2 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

The EDEM2 (ER degradation-enhancing α-mannosidase-like protein 2) antibody is a tool used to study the ER-associated degradation (ERAD) pathway, a critical quality control system in the endoplasmic reticulum (ER). EDEM2. a member of the EDEM family (EDEM1-3), facilitates the recognition and targeting of misfolded glycoproteins for proteasomal degradation. Unlike EDEM1 and EDEM3. EDEM2 lacks enzymatic mannosidase activity but acts as a lectin-like chaperone, binding to high-mannose oligosaccharides (e.g., Man8GlcNAc2) on unfolded glycoproteins to accelerate their ERAD. It collaborates with ER-resident chaperones like BiP/GRP78 and interacts with ERAD machinery components such as SEL1L-HRD1.

EDEM2 antibodies are widely employed in research to investigate protein quality control mechanisms, ER stress responses, and diseases linked to ERAD dysfunction, including neurodegenerative disorders (e.g., Alzheimer’s, Parkinson’s), metabolic syndromes, and cancer. These antibodies enable detection and localization of EDEM2 via techniques like Western blotting, immunofluorescence, and immunoprecipitation. Studies using EDEM2 antibodies have revealed its role in regulating the stability of specific substrates, such as α1-antitrypsin variants, and its involvement in adaptive ER stress pathways like the unfolded protein response (UPR). Recent research also explores its potential as a therapeutic target for conditions associated with protein misfolding. Antibodies are typically raised in rabbits or mice, with validation in knockout models ensuring specificity.